TAK-875 er-5 In vitro cytotoxicity and in

In vitro cytotoxicity and in vivo efficacy

Smiles: CCC1=NN(CCO)C(CC)=C1OC1C=C(C=C(C=1)C#N)C#N

and reverses aberrant tau-phosphorylation and rescues repressed calcineurin/NFAT signaling

BGT226 induced autophagy as indicated by the aggregation and upregulation of the microtubule-associated protein light chain 3B-II

Arsenijevic N

TAK-875 er-5 In vitro cytotoxicity and inTAK 875, is a potent, selective, and orally bioavailable GPR40 agonist, with a pharmacokinetic profile enabling long acting drug efficacy. TAK 875 showed potent plasma glucose lowering action and insulinotropic action during an oral glucose tolerance test in female Wistar fatty rats with impaired glucose tolerance. TAK 875 is currently in clinical trials for the treatment of type 2 diabetes mellitus. Product information CAS Number: 1000413 72 8